Broken String Biosciences is a genomics company with the goal of developing safer cell and gene therapies by assessing the stability of the genome. Its core technology, INDUCE-seq™, is a Next Generation Sequencing-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and to evaluate the associated genetic outcomes. Broken String Biosciences was spun out of Cardiff University in 2020 and completed a six-month residency at the Illumina Accelerator in Cambridge, UK.
Hypervision Surgical is a King’s College London spin-out that aims to revolutionise the outcomes of surgical interventions. They achieve this by harnessing AI and clinical edge computing to augment a surgeon’s ability to assess the status of tissue, to distinguish between different tissue types, and to discriminate healthy from unhealthy tissue.
ImmuneSpec has developed a proprietary approach & process to conduct highly sensitive MAPPS assays, i.e., the analysis of MHC-associated peptide proteomics. This immunogenicity testing indicates whether a protein drug will result in a potential activation of the immune system. ImmuneSpec offers their expertise through a service model to players active in the drug discovery space, where early identification of candidates results in a significant cost & time saving.
Aspect Analytics supports leading stakeholders in pharmaceutical research, biomarker discovery and diagnostics via high-end bioinformatics software for spatial omics. Their cloud-based platform enables the management, analysis and integration of spatial omics data across experiments and across technologies to obtain holistic, spatially resolved insights of the molecular composition of tissues.
Amaron is the premier healthcare software connector in the Benelux and France. The Amaron product suite enables hospitals to connect disparate software tools, build workflows and standardise data structures across a vast array of software used in hospitals.
BlueBee is a customizable, cloud-based next generation sequencing (NGS)platform that enables rapid scalability, global compliance, and international collaboration.
Thirona is specialized in the field of AI assisted medical image analysis in the pulmonary and ophthalmology segments. They develop solutions for diagnosis, patient follow-up, and treatment selection based on lung (CT scans and X-rays) and retina scans. They offer their solutions to players active in clinical trials, hospitals, pharmaceutical players, and OEMs.
icometrix is the world leader in software solutions to obtain clinically meaningful data from brain MRI and CT scans for patients with Multiple Sclerosis, Traumatic Brain Injury, Epilepsy, Alzheimer’s Disease, Stroke, etc.
LynxCare collaborates with healthcare organisations and Life Sciences companies to allow them to leverage data, both structured and unstructured. Via the platform supported by Natural Language Processing technology, LynxCare creates Real-World Evidence & management data hubs which prove to be valuable for market intelligence, market access studies and R&D insights. In line with the legal framework, GDPR compliance is deeply embedded in the core of the technology and business.
ONTOFORCE develops breakthrough semantic search technology enabling enterprise wide liked data solutions. The award-winning user-friendly platform DISQOVER builds intelligent links between private, third-party, and public data sources democratising access to all your data. DISQOVER turns data into smart and actionable data.
PharmaFluidics introduces a new generation of chromatography columns, based on top-level academic research demonstrating the effects of order and disorder in particulate-based separation systems.
FOx Biosystems technology is based on an innovative fiber-optic-based surface plasmon resonance biosensor. It enables users to generate high quality biomolecular data such as affinity data, kinetic data and concentration measurements.
We are open to novel investments and are always planning the next funds and investment strategies. Leave your details below and our partners will be in touch.
Submit your pitch below. We receive dozens of pitches each week and process these dilligently. We might not be able to get back to you immediately.